🇺🇸 FDA
Patent

US 7718196

Rapamycin-resistant T cells and therapeutic uses thereof

granted A61KA61K2035/122A61K2035/124

Quick answer

US patent 7718196 (Rapamycin-resistant T cells and therapeutic uses thereof) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2035/122, A61K2035/124, A61K2039/57, A61K2239/31